Whistleblower: Genentech put trial subjects at risk in rushed study

A senior Genentech researcher filed a whistleblower suit alleging that the company double-timed a high-profile Pi3 Kinase study, putting patients at risk in the process. According to the suit, Genentech disregarded clinical standards to hurry the study along, fearing that Roche ($RHHBY)--now its parent company--would take the drug away if officials saw the researcher's slower timelines. Report

Like what you're reading?
Click here to get more news like this delivered to your inbox>>